Interplay between programmed death-ligand 1 and non-coding RNAs
暂无分享,去创建一个
[1] Zhengxin Cai,et al. Histone Methyltransferase SETDB1 Promotes Immune Evasion in Colorectal Cancer via FOSB-Mediated Downregulation of MicroRNA-22 through BATF3/PD-L1 Pathway , 2022, Journal of immunology research.
[2] Weiwei Tang,et al. Inhibition of PARP Potentiates Immune Checkpoint Therapy through miR-513/PD-L1 Pathway in Hepatocellular Carcinoma , 2022, Journal of oncology.
[3] Xinwei Qiao,et al. Long non-coding RNA Opa interacting protein 5-antisense RNA 1 binds to micorRNA-34a to upregulate oncogenic PD-L1 in non-small cell lung cancer , 2022, Bioengineered.
[4] Yuan Gao,et al. Increased PD-L1 Expression in Acquired Cisplatin-Resistant Lung Cancer Cells via Mir-181a. , 2022, The Tohoku journal of experimental medicine.
[5] Mei Liu,et al. Serum exosomal miR‐16‐5p functions as a tumor inhibitor and a new biomarker for PD‐L1 inhibitor‐dependent immunotherapy in lung adenocarcinoma by regulating PD‐L1 expression , 2022, Cancer medicine.
[6] M. Taheri,et al. Interplay Between Non-Coding RNAs and Programmed Cell Death Proteins , 2022, Frontiers in Oncology.
[7] Yan Luo,et al. HOXA-AS3 Promotes Proliferation and Migration of Hepatocellular Carcinoma Cells via the miR-455-5p/PD-L1 Axis , 2021, Journal of immunology research.
[8] M. Taheri,et al. Regulatory Role of Non-Coding RNAs on Immune Responses During Sepsis , 2021, Frontiers in Immunology.
[9] Yun Li,et al. MicroRNA-889-3p restrains the proliferation and epithelial–mesenchymal transformation of lung cancer cells via down-regulation of Homeodomain-interacting protein kinase 1 , 2021, Bioengineered.
[10] Kun Xu,et al. Thalidomide suppresses angiogenesis and immune evasion via lncRNA FGD5-AS1/miR-454-3p/ZEB1 axis-mediated VEGFA expression and PD-1/PD-L1 checkpoint in NSCLC. , 2021, Chemico-biological interactions.
[11] Zhi-wei Wang,et al. The role of lncRNAs and circRNAs in the PD-1/PD-L1 pathway in cancer immunotherapy , 2021, Molecular cancer.
[12] Xiaohui Wang,et al. c‐Myb facilitates immune escape of esophageal adenocarcinoma cells through the miR‐145‐5p/SPOP/PD‐L1 axis , 2021, Clinical and translational medicine.
[13] Jin-Moo Lee,et al. Mechanistic Insights of Anti-Immune Evasion by Nobiletin through Regulating miR-197/STAT3/PD-L1 Signaling in Non-Small Cell Lung Cancer (NSCLC) Cells , 2021, International journal of molecular sciences.
[14] J Zhang,et al. Exosomal circEIF3K from cancer-associated fibroblast promotes colorectal cancer (CRC) progression via miR-214/PD-L1 axis , 2021, BMC cancer.
[15] M. Taheri,et al. Role of lncRNA BANCR in Human Cancers: An Updated Review , 2021, Frontiers in Cell and Developmental Biology.
[16] Wei Yang,et al. miR-526b-3p inhibits lung cancer cisplatin-resistance and metastasis by inhibiting STAT3-promoted PD-L1 , 2021, Cell Death & Disease.
[17] Changping Wu,et al. Hsa_circ_0136666 activates Treg-mediated immune escape of colorectal cancer via miR-497/PD-L1 pathway. , 2021, Cellular signalling.
[18] Lei Wang,et al. LncRNA KCNQ1OT1 Secreted by Tumor Cell-Derived Exosomes Mediates Immune Escape in Colorectal Cancer by Regulating PD-L1 Ubiquitination via MiR-30a-5p/USP22 , 2021, Frontiers in Cell and Developmental Biology.
[19] Jingbo Wang,et al. MicroRNA-326 attenuates immune escape and prevents metastasis in lung adenocarcinoma by targeting PD-L1 and B7-H3 , 2021, Cell death discovery.
[20] Yan Li,et al. miR-194-5p down-regulates tumor cell PD-L1 expression and promotes anti-tumor immunity in pancreatic cancer. , 2021, International immunopharmacology.
[21] F. Slack,et al. miR-105-5p regulates PD-L1 expression and tumor immunogenicity in gastric cancer. , 2021, Cancer letters.
[22] Xue-guang Zhang,et al. Circular RNA hsa_circ_0003288 induces EMT and invasion by regulating hsa_circ_0003288/miR-145/PD-L1 axis in hepatocellular carcinoma , 2021, Cancer Cell International.
[23] B. Baradaran,et al. MicroRNA‐124‐3p suppresses PD‐L1 expression and inhibits tumorigenesis of colorectal cancer cells via modulating STAT3 signaling , 2021, Journal of cellular physiology.
[24] H. M. El Tayebi,et al. Oleuropin controls miR-194/XIST/PD-L1 loop in triple negative breast cancer: New role of nutri-epigenetics in immune-oncology. , 2021, Life sciences.
[25] D. Geller,et al. Interferon regulatory factor 1 (IRF-1) downregulates Checkpoint kinase 1 (CHK1) through miR-195 to upregulate apoptosis and PD-L1 expression in Hepatocellular carcinoma (HCC) cells , 2021, British Journal of Cancer.
[26] M. Dinger,et al. The Impact of Non-coding RNAs in the Epithelial to Mesenchymal Transition , 2021, Frontiers in Molecular Biosciences.
[27] Min Zhang,et al. LncRNA PROX1-AS1 Facilitates Gastric Cancer Progression via miR-877-5p/PD-L1 Axis , 2021, Cancer management and research.
[28] Jun Ren,et al. LncRNA SNHG1 regulates immune escape of renal cell carcinoma by targeting miR‐129‐3p to activate STAT3 and PD‐L1 , 2021, Cell biology international.
[29] Kun Du,et al. Circular RNA CHST15 Sponges miR-155-5p and miR-194-5p to Promote the Immune Escape of Lung Cancer Cells Mediated by PD-L1 , 2021, Frontiers in Oncology.
[30] Chinmoy Ghosh,et al. A snapshot of the PD-1/PD-L1 pathway , 2021, Journal of Cancer.
[31] Xiang Yu,et al. HIF1A-AS2 Promotes the Proliferation and Metastasis of Gastric Cancer Cells Through miR-429/PD-L1 Axis , 2021, Digestive Diseases and Sciences.
[32] S. Zeng,et al. miR-224-5p Contained in Urinary Extracellular Vesicles Regulates PD-L1 Expression by Inhibiting Cyclin D1 in Renal Cell Carcinoma Cells , 2021, Cancers.
[33] Xiaoming Wang,et al. LncRNA UCA1 attenuated the killing effect of cytotoxic CD8 + T cells on anaplastic thyroid carcinoma via miR-148a/PD-L1 pathway , 2021, Cancer Immunology, Immunotherapy.
[34] F. Ning,et al. The EGFR‐P38 MAPK axis up‐regulates PD‐L1 through miR‐675‐5p and down‐regulates HLA‐ABC via hexokinase‐2 in hepatocellular carcinoma cells , 2021, Cancer communications.
[35] Jing Liu,et al. miR‑576‑3p overexpression enhances cisplatin sensitivity of ovarian cancer cells by dysregulating PD‑L1 and cyclin D1. , 2020, Molecular medicine reports.
[36] Heng Zhang,et al. Tumor-derived extracellular vesicles containing microRNA-1290 promote immune escape of cancer cells through the Grhl2/ZEB1/PD-L1 axis in gastric cancer. , 2020, Translational research : the journal of laboratory and clinical medicine.
[37] P. Dong,et al. PD-L1 Is a Tumor Suppressor in Aggressive Endometrial Cancer Cells and Its Expression Is Regulated by miR-216a and lncRNA MEG3 , 2020, Frontiers in Cell and Developmental Biology.
[38] Ai-Jun Li,et al. Dual targeting of PD-L1 and PD-L2 by PCED1B-AS1 via sponging hsa-miR-194-5p induces immunosuppression in hepatocellular carcinoma , 2020, Hepatology International.
[39] Ji Wang,et al. LncRNA NUTM2A‐AS1 positively modulates TET1 and HIF‐1A to enhance gastric cancer tumorigenesis and drug resistance by sponging miR‐376a , 2020, Cancer medicine.
[40] Tao Li,et al. LINC00657 knockdown suppresses hepatocellular carcinoma progression by sponging miR-424 to regulate PD-L1 expression , 2020, Genes & genomics.
[41] Chengyi Sun,et al. LncRNA PSMB8-AS1 contributes to pancreatic cancer progression via modulating miR-382-3p/STAT1/PD-L1 axis , 2020, Journal of experimental & clinical cancer research : CR.
[42] Hanshuo Zhang,et al. miR-502-5p affects gastric cancer progression by targeting PD-L1 , 2020, Cancer Cell International.
[43] B. Baradaran,et al. Tumor suppressive activity of miR-424-5p in breast cancer cells through targeting PD-L1 and modulating PTEN/PI3K/AKT/mTOR signaling pathway. , 2020, Life sciences.
[44] Yun Liu,et al. Inhibition of Lnc-OC1 Induced Cell Apoptosis and Decreased Cell Viability by Releasing miR-34a and Inhibiting PD-L1 in Endometrial Carcinoma , 2020, Reproductive Sciences.
[45] M. Xue,et al. Circular RNA circ-CPA4/ let-7 miRNA/PD-L1 axis regulates cell growth, stemness, drug resistance and immune evasion in non-small cell lung cancer (NSCLC) , 2020, Journal of experimental & clinical cancer research : CR.
[46] Kai Yin,et al. LncRNA SNHG15 Contributes to Immuno-Escape of Gastric Cancer Through Targeting miR141/PD-L1 , 2020, OncoTargets and therapy.
[47] Ce Li,et al. PD-L1 Under Regulation of miR-429 Influences the Sensitivity of Gastric Cancer Cells to TRAIL by Binding of EGFR , 2020, Frontiers in Oncology.
[48] Yanlv Ren,et al. LncRNA GATA3‐AS1 facilitates tumour progression and immune escape in triple‐negative breast cancer through destabilization of GATA3 but stabilization of PD‐L1 , 2020, Cell proliferation.
[49] W. Zhu,et al. MiR-92 overexpression suppresses immune cell function in ovarian cancer via LATS2/YAP1/PD-L1 pathway , 2020, Clinical and Translational Oncology.
[50] Min Zhang,et al. MicroRNA-138-5p Suppresses Non-small Cell Lung Cancer Cells by Targeting PD-L1/PD-1 to Regulate Tumor Microenvironment , 2020, Frontiers in Cell and Developmental Biology.
[51] Ran Wei,et al. Clinical and Recent Patents Applications of PD-1/PD-L1 Targeting Immunotherapy in Cancer Treatment—Current Progress, Strategy, and Future Perspective , 2020, Frontiers in Immunology.
[52] Dong Li,et al. Programmed Death Ligand-1 (PD-L1) Regulated by NRF-2/MicroRNA-1 Regulatory Axis Enhances Drug Resistance and Promotes Tumorigenic Properties in Sorafenib-Resistant Hepatoma Cells , 2020, Oncology research.
[53] Li Li,et al. Circular RNA circ_0000284 plays an oncogenic role in the progression of non-small cell lung cancer through the miR-377-3p-mediated PD-L1 promotion , 2020, Cancer Cell International.
[54] R. Liu,et al. Exosome-delivered miR-15a/16 target PD-L1 to inhibit immune escape in gastric cancer , 2020 .
[55] J. Ji,et al. MicroRNA‐155‐5p suppresses PD‐L1 expression in lung adenocarcinoma , 2020, FEBS open bio.
[56] Meng Li,et al. LncRNA EMX2OS Induces Proliferation, Invasion and Sphere Formation of Ovarian Cancer Cells via Regulating the miR-654-3p/AKT3/PD-L1 Axis , 2020, Cancer management and research.
[57] Yuanting Gu,et al. Cancer-associated fibroblasts-derived exosomes suppresses immune cell function in breast cancer via miR-92/PD-L1 pathway , 2020 .
[58] Bahareh Yazdani,et al. Fine-tuning ofroutine combined first- trimester screening: The ratio of serum-free- beta-human chorionic gonadotropin (fβ-hCG) to pregnancy-associated plasma protein-A (PAPP-A) could improve performance of Down syndrome screening program, a retrospective cohort study in Iran. , 2020, Human antibodies.
[59] Yilin Chen,et al. MicroRNA‐93‐5p expression in tumor tissue and its tumor suppressor function via targeting programmed death ligand‐1 in colorectal cancer , 2020, Cell biology international.
[60] Jun Wang,et al. MicroRNA-200a induces immunosuppression by promoting PTEN-mediated PD-L1 upregulation in osteosarcoma , 2020, Aging.
[61] Jun Zhang,et al. LINC00657 activates PD‐L1 to promote osteosarcoma metastasis via miR‐106a , 2020, Journal of cellular biochemistry.
[62] Zhijun Wang,et al. Cisplatin‐mediated down‐regulation of miR‐145 contributes to up‐regulation of PD‐L1 via the c‐Myc transcription factor in cisplatin‐resistant ovarian carcinoma cells , 2019, Clinical and experimental immunology.
[63] Ye Kang,et al. Long noncoding RNA LINC00473 drives the progression of pancreatic cancer via upregulating programmed death‐ligand 1 by sponging microRNA‐195‐5p , 2019, Journal of cellular physiology.
[64] G. Ji,et al. miR-140-3p Suppresses Cell Growth And Induces Apoptosis In Colorectal Cancer By Targeting PD-L1 , 2019, OncoTargets and therapy.
[65] Bin Zhang,et al. Polydatin Exerts an Antitumor Effect Through Regulating miR-382/PD-L1 Axis in Colorectal Cancer. , 2019, Cancer biotherapy & radiopharmaceuticals.
[66] A. Naing,et al. Probody Therapeutics: An Emerging Class of Therapies Designed to Enhance On-Target Effects with Reduced Off-Tumor Toxicity for Use in Immuno-Oncology , 2019, Clinical Cancer Research.
[67] M. Otsuka,et al. Expression of circular RNA CDR1‑AS in colon cancer cells increases cell surface PD‑L1 protein levels. , 2019, Oncology reports.
[68] Y. Liu,et al. LncRNA SNHG14/miR-5590-3p/ZEB1 positive feedback loop promoted diffuse large B cell lymphoma progression and immune evasion through regulating PD-1/PD-L1 checkpoint , 2019, Cell Death & Disease.
[69] Guang-Yu Lian,et al. LncRNA MALAT1 promotes tumorigenesis and immune escape of diffuse large B cell lymphoma by sponging miR-195. , 2019, Life sciences.
[70] Meng Yang,et al. miR3609 sensitizes breast cancer cells to adriamycin by blocking the programmed death‐ligand 1 immune checkpoint , 2019, Experimental cell research.
[71] Qi Zhou,et al. A novel protein encoded by a circular RNA circPPP1R12A promotes tumor pathogenesis and metastasis of colon cancer via Hippo-YAP signaling , 2019, Molecular Cancer.
[72] Xiaomin Song,et al. FcγR-Binding Is an Important Functional Attribute for Immune Checkpoint Antibodies in Cancer Immunotherapy , 2019, Front. Immunol..
[73] Shuquan Wei,et al. LncRNA MALAT1 contributes to non-small cell lung cancer progression via modulating miR-200a-3p/programmed death-ligand 1 axis , 2019, International journal of immunopathology and pharmacology.
[74] X. Zhang,et al. MicroRNA-497-5p down-regulation increases PD-L1 expression in clear cell renal cell carcinoma , 2018, Journal of drug targeting.
[75] J. Wan,et al. miR-142-5p regulates CD4+ T cells in human non-small cell lung cancer through PD-L1 expression via the PTEN pathway , 2018, Oncology reports.
[76] Yun Wu,et al. The miR‐3127‐5p/p‐STAT3 axis up‐regulates PD‐L1 inducing chemoresistance in non‐small‐cell lung cancer , 2018, Journal of cellular and molecular medicine.
[77] Y. Lou,et al. Next generation of immune checkpoint therapy in cancer: new developments and challenges , 2018, Journal of Hematology & Oncology.
[78] Changping Wu,et al. Overexpressed miR-195 attenuated immune escape of diffuse large B-cell lymphoma by targeting PD-L1. , 2018, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
[79] Yi Wang,et al. miR-34a attenuates glioma cells progression and chemoresistance via targeting PD-L1 , 2017, Biotechnology Letters.
[80] Lei Wang,et al. miR-217 inhibits laryngeal cancer metastasis by repressing AEG-1 and PD-L1 expression , 2017, Oncotarget.
[81] Zhenyi Xue,et al. miR-142-5p regulates tumor cell PD-L1 expression and enhances anti-tumor immunity. , 2017, Biochemical and biophysical research communications.
[82] Aiwu Zhou,et al. Structural basis of a novel PD-L1 nanobody for immune checkpoint blockade , 2017, Cell Discovery.
[83] B. Spellberg,et al. Type 1/Type 2 immunity in infectious diseases. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.